Brief: Cadrenal Boosts Anticoagulation Pipeline With Acquisition Of eXIthera’s Factor XIa Inhibitor Portfolio
15/09/2025 13:22
Sept 15 (Reuters) - Cadrenal Therapeutics Inc CVKD.O: CADRENAL THERAPEUTICS ENHANCES ANTICOAGULATION PIPELINE THROUGH ACQUISITION OF EXITHERA’S PORTFOLIO OF FACTOR XIA INHIBITORS CADRENAL THERAPEUTICS INC - EXITHERA TO RECEIVE UP TO $15 MILLION IN MILESTONE PAYMENTS Source text: ID:nGNXb2tFvD Further company coverage: CVKD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cadrenal Therapeutics
See all newsCadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Cadrenal Therapeutics Q2 net loss narrows as operating expenses fall
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology